Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from BONESUPPORT HOLDING AB ( (SE:BONEX) ) is now available.
BONESUPPORT announced promising results from a study presented at the European Bone and Joint Infection Society meeting, demonstrating that their CERAMENT G and CERAMENT V products are effective in treating post-traumatic and chronic bone infections in resource-limited settings. The study’s success in a developing market underscores the products’ versatility and potential for global application, reinforcing their efficacy and safety without reliance on advanced infrastructure.
The most recent analyst rating on (SE:BONEX) stock is a Buy with a SEK346.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.
More about BONESUPPORT HOLDING AB
BONESUPPORT is a company specializing in orthobiology, focusing on developing and commercializing innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have drug-eluting capabilities. Based in Lund, Sweden, the company is known for its CERAMENT products and reported net sales of SEK 899 million in 2024.
YTD Price Performance: -21.30%
Average Trading Volume: 144,545
Technical Sentiment Signal: Buy
Current Market Cap: SEK20.05B
See more insights into BONEX stock on TipRanks’ Stock Analysis page.